Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acarix ABACIXF -0.01%39 3-Year EBITDA Growth Rate is 47.80% as of Mar. 2026, which is 85% above its 10-year median of 25.90. GuruFocus rates ACIXF with a GF Score™ of 39/100 and a GF Value™ of $0.02 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 694 Medical Devices & Instruments companies, Acarix AB ranks better than 87.9% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 47.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 37.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 27.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Acarix AB was 47.80% per year. The lowest was -22.00% per year. And the median was 25.90% per year.
Acarix AB (OTCPK:ACIXF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Acarix AB 3-Year EBITDA Growth Rate Related Terms
ACIXF vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Acarix AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Acarix AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 47.80% mean?
Acarix AB (ACIXF) has a 3-Year EBITDA Growth Rate of 47.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Acarix AB and its competitors. This is 85% above median its historical median of 25.90. According to the industry distribution chart, Acarix AB ranks #84 out of 694 companies in the Medical Devices & Instruments industry, placing it in the top 12.1%.
Is Acarix AB's 3-Year EBITDA Growth Rate too high?
Acarix AB's current 3-Year EBITDA Growth Rate of 47.80% is 85% above median its 10-year median of 25.90. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.55. Acarix AB's value of 47.80% is 533.1% above this industry median. Based on the distribution chart, Acarix AB ranks #84 out of 694 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Acarix AB has a GF Score™ of 39/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acarix AB ranks #84 out of 694 companies for 3-Year EBITDA Growth Rate. This places Acarix AB in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 7.55. Acarix AB's value of 47.80% is 533.1% above this benchmark. While the company's 10-year median is 25.90 vs. the industry median of 7.55, Acarix AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.55, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acarix AB's current 3-Year EBITDA Growth Rate of 47.80% is 533.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Acarix AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acarix AB's current 3-Year EBITDA Growth Rate is 47.80%, which is 85% above median its own 10-year median of 25.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 30.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 47.80%, which is 85% above median its 10-year median of 25.90 and 533.1% above the Medical Devices & Instruments industry median of 7.55. Acarix AB's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Acarix AB (ACIXF), the current 3-Year EBITDA Growth Rate is 47.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (ACIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of $0.03 is trading 30.3% above its estimated GF Value™ of $0.02.
GuruFocus considers Acarix AB to be Modestly Overvalued.
Key valuation signals for ACIXF:
3-Year EBITDA Growth Rate: 47.80% (85% above median its 10-year median of 25.90)
GF Value™: $0.02 vs. price of $0.03 (30.3% above fair value)
Industry Position: 533.1% above the Medical Devices & Instruments median (#84 of 694)
No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
39GF Score
Get the complete analysis for ACIXF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIXF has been successfully added to your 
